Alaric DeArment

Reporter at Scrip

Featured in: Favicon

informa.com (+3) Favicon

forbes.com Favicon

medium.com Favicon

nydailynews.com Favicon

sun-sentinel.com Favicon

newrepublic.com Favicon

abovethelaw.com Favicon

medcitynews.com Favicon

geneticliteracyproject.org Favicon

dealbreaker.com + 6 more

Articles

Takeda Plans US Investment But Sees Little Impact From Tariffs

1 week ago | insights.citeline.com | Alaric DeArment

Takeda Plans US Investment But Sees Little Impact From TariffsThe Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.
Gilead Joins Pharma’s US Investment Rush

1 week ago | insights.citeline.com | Alaric DeArment

Gilead Joins Pharma’s US Investment RushThe company drew praise from the Trump administration as one of multiple companies announcing multibillion-dollar investments in US manufacturing and R&D.
BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

1 week ago | insights.citeline.com | Alaric DeArment

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOneThe biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.
Atara Does An About Face As FDA Lifts Ebvallo Hold

1 week ago | insights.citeline.com | Alaric DeArment

Atara Does An About Face As FDA Lifts Ebvallo HoldThe biotech said it will have a type A meeting with the agency to resubmit for the cell therapy’s approval in EBV+ PTLD.
BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

1 week ago | insights.citeline.com | Alaric DeArment

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.
Lilly’s Ricks Urges Trump To Pick Tax Incentives Instead Of Tariffs

2 weeks ago | insights.citeline.com | Alaric DeArment

Lilly’s Ricks Urges Trump To Pick Tax Incentives Instead Of Tariffs On Lilly’s Q1 earnings call, CEO David Ricks voiced concerns about the Trump Administration’s tariff policy, which he said could adversely affect Lilly and the industry as a whole.
Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

2 weeks ago | insights.citeline.com | Alaric DeArment

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts ShadowLilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.
Another Regeneron CRL Prompts Regulatory Operations Questions

2 weeks ago | insights.citeline.com | Alaric DeArment

Another Regeneron CRL Prompts Regulatory Operations QuestionsCEO Len Schleifer said during the company’s first quarter earnings call that most of the complete response letters the company has received related to third-party suppliers, not efficacy or safety. The Eylea HD complete response letter could delay its launch beyond mid-year. • Source: Shutterstock
Novartis Gains Further Renal Territory With Regulus Acquisition

2 weeks ago | insights.citeline.com | Alaric DeArment

Novartis Gains Further Renal Territory With Regulus AcquisitionThe San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
Another CRL Prompts Questions About Regeneron’s Regulatory Operations

2 weeks ago | insights.citeline.com | Alaric DeArment

Another CRL Prompts Questions About Regeneron’s Regulatory OperationsCEO Len Schleifer explained on the company’s Q1 earnings call that most of the complete response letters the company has received related to third-party suppliers, not efficacy or safety.